TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04005690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azenosertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT02344550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus(afinitor)
Description: Everolimus 10mg p.o. daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg p.o. daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg p.o. daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide(Lorelin Depot)
Description: Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide(Lorelin Depot)
Description: Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
Study: NCT00406393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged \< 12.0 years OR weighing \< 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL.
Study: NCT03390790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel 2%
Description: If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard lubricant gel
Description: If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
Study: NCT03946995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling Group
Description: Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed. Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.~The treatment will be continued for 2 weeks with 2 sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graston Technique Group
Description: Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed.~Later, lubricant will be applied to the skin, and Graston technique will be applied using instrument over the active myofascial trigger points in upper trapezius.~The treatment will be continued for 2 weeks with 2 sessions per week.
Study: NCT02995135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)
Study: NCT03257592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]DPA-713
Description: \[11C\]DPA-713 PET imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]DPA-713
Description: \[11C\]DPA-713 PET imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]DPA-713
Description: \[11C\]DPA-713 PET imaging
Study: NCT02995135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFP Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT02985060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun
Description: 1. Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~   Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~2. Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~3. Recovery phase:Rewarming velocity: 0.05\~0.1℃ (within 30 hours)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: 1. All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~2. In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~3. Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~4. Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study: NCT02355847

Intervention type: OTHER
Group type: OTHER
Intervention: Lectures
Description: Lectures
Study: NCT00555204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 10 mg - capsules once daily for 12 weeks
Study: NCT04076007

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Study: NCT00719173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT01899378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum infantis
Description: 10\^9 CFU
Study: NCT00719173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT04063683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride, Paclitaxel, cisplatin
Description: * anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle.
Study: NCT03684083

Intervention type: PROCEDURE
Intervention: bronchial biopsies
Description: bronchial fibroscopy with bronchial biopsies

Intervention type: PROCEDURE
Intervention: bronchial biopsies
Description: bronchial fibroscopy with bronchial biopsies
Study: NCT03374332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin (GO)
Description: Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin (GO)
Description: Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Leukocytes
Description: The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Leukocytes
Description: The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
Study: NCT03897010

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Socket Graft
Description: 5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Graft
Description: 5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
Study: NCT04269187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline oral 200 mg daily for 12 days
Study: NCT00641212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04188509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
Study: NCT01923974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03935399

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: 10 IU oxytocin (Pitocin) for intramuscular injection

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: 1.5 ml preservative free saline for intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1.5 ml preservative free saline for intramuscular injection
Study: NCT00350454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapamycin-eluting Stent with permanent polymer
Description: due to randomization, rapamycin-eluting stent with permanent polymer will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapamycin-eluting stent with biodegradable polymer
Description: due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
Study: NCT01512251

Intervention type: DRUG
Group type: OTHER
Intervention: BKM120 Combined with Vemurafenib (PLX4032)
Description: Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D
Study: NCT02084186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: herb-partitioned moxibustion
Description: Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: bran-partitioned moxibustion
Description: Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
Study: NCT00350454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polymer-free, rapamycin-eluting stent
Description: due to randomization, polymer-free.rapamycin-eluting stent will be implanted
Study: NCT01280045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VAGINAL HYSTERECTOMY
Description: GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
Study: NCT00555204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 5 mg - capsules once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 15 mg - capsules once daily for 12 weeks
Study: NCT01280045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VAGINAL HYSTERECTOMY
Description: GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
Study: NCT03625271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The PEER Report
Description: PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
Study: NCT01784627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: c-ASBI
Description: Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
Study: NCT00555204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 20 mg - capsules once daily for 12 weeks
Study: NCT04076007

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate depleted beetroot juice
Study: NCT03425422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITARIA System
Description: Chronic stimulation of the right cervical vagus nerve
Study: NCT01565499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study: NCT03097354

Intervention type: OTHER
Intervention: no intervention/observational survey study design
Description: no intervention/observational survey study design
Study: NCT00555204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 30 mg - capsules once daily for 12 weeks
Study: NCT02900001

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early coronary angiography
Description: Routine coronary angiography and revascularization if appropriate within 24 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed coronary angiography
Description: Routine coronary angiography and revascularization if appropriate after 72 hours
Study: NCT01417182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFBC
Description: A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
Study: NCT04213521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory balance exercise
Description: Multisensory balance training describes a balance exercise incorporating individual sensory manipulation of vision, vestibular, proprioception and sensory integration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional balance exercise
Description: such as static and dynamic standing balance without altered sensory inputs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional balance exercise
Description: such as static and dynamic standing balance without altered sensory inputs.
Study: NCT02410733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipo-MERIT
Description: vaccination
Study: NCT01957527

Intervention type: DEVICE
Intervention: Peripheral arterial tonometry (EndoPAT)
Study: NCT04500275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Hydrochloride
Description: Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
Study: NCT04443751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1702
Description: SHR-1702 monotherapy, administered IV
Study: NCT00555204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 35 mg - capsules once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo - capsules once daily for 12 weeks
Study: NCT03024320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M2M
Description: An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic \& 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic \& 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M2M
Description: An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic \& 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic \& 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Telecoaching on health-based topics, not including physical activity.
Study: NCT05180747

Intervention type: OTHER
Group type: OTHER
Intervention: Frequency of physical therapy sessions
Description: Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Frequency of physical therapy sessions
Description: Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.
Study: NCT00413608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel
Study: NCT02373462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: other anti-hypertensive drug
Description: CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
Study: NCT03141853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine-assisted Therapy
Description: Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arthritis Exercise Education
Description: Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
Study: NCT02740257

Intervention type: OTHER
Intervention: Photos
Description: Photos will be taken of skin lesion markings using a smart phone or tablet

Intervention type: OTHER
Intervention: Photos
Description: Photos will be taken of skin lesion markings using a smart phone or tablet